Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Yohann Loriot, Cora N. Sternberg, Daniel Castellano, Sjoukje F. Oosting, Herlinde Dumez, Robert Huddart, Karina Vianna, Teresa Alonso Gordoa, Iwona Skoneczna, André P. Fay, Franco Nolè, Francesco Massari, Birutė Brasiūnienė, Pablo Maroto, Simon Fear, Flavia Di Nucci, Sabine de Ducla, Ernest Choy
Topics & Concepts
AtezolizumabMedicineDiscontinuationClinical endpointInternal medicineAdverse effectSubgroup analysisPopulationOncologyClinical trialSurgeryImmunotherapyCancerConfidence intervalNivolumabEnvironmental healthBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersRenal Diseases and Glomerulopathies